Clinical Practice
Popular
Urs Weber, MD
Urs Weber, MD
Christopher Cann, MD
Steve Jackson, PharmD
Nisha Joseph, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Alessandra Tedeschi, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODEMinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
Irene Su, MD, MSCE
Erica L. Mayer, MD, MPH
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
